The U.S. Department of Health and Human Services has started discussions with pharmaceutical companies about implementing President Trump's most-favored-nation pricing proposal. The initiative seeks to make American prescription drug prices match those found in other developed nations.

Federal health officials announced Thursday they have initiated conversations with drug manufacturers regarding legislation to implement President Donald Trump’s most-favored-nation pricing proposal.
Chris Klomp, chief counselor for the U.S. Department of Health and Human Services, stated the administration has started briefing pharmaceutical companies on the initiative. The plan would bring American prescription medication prices in line with costs seen in other developed nations worldwide.
The most-favored-nation approach represents the Trump administration’s effort to reduce prescription drug expenses for American consumers by matching international pricing standards.
President Urges Israel to Halt Energy Strikes as Middle East Crisis Worsens
Defense Startup to Begin Drone Manufacturing at Ohio Facility
SEC Creates New Accounting Watchdog Unit While Cutting Oversight Board Staff
Powerful Cyclone Narelle Threatens Australia’s Northeast Coast